%0 Journal Article
%T Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (Abraxane£¿) for peritoneal carcinomatosis ¨C a phase I first-in-human study
%A Leen Van De Sande
%A Marc Pocard
%A Marc Reymond
%A Marco Vaira
%A Martin Graversen
%A Martin Hubner
%A Sarah Cosyns
%A Wim Ceelen
%A Wouter Willaert
%J Archive of "Pleura and Peritoneum".
%D 2018
%R 10.1515/pp-2018-0112
%X Nanoparticles hold considerable promise for aerosol-based intraperitoneal delivery in patients with carcinomatosis. Recently, results from preclinical and early clinical trials suggested that albumin-bound paclitaxel (ABP, Abraxane£¿) may result in superior efficacy in the treatment of peritoneal metastases (PM) compared to the standard solvent-based paclitaxel formulation (Taxol£¿). Here, we propose a phase I study of pressurized intraperitoneal aerosol chemotherapy (PIPAC) using ABP in patients with upper Gastrointestinal, breast, or ovarian cancer
%K Abraxane
%K aerosol
%K albumin
%K carcinomatosis
%K intraperitoneal
%K pressurized intraperitoneal aerosol chemotherapy (PIPAC).
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405003/